key: cord-0902164-8vvhen5w
authors: Karakike, Eleni; Giamarellos-Bourboulis, Evangelos J.; Kyprianou, Miltiades; Fleischmann-Struzek, Carolin; Pletz, Mathias W.; Netea, Mihai G.; Reinhart, Konrad; Kyriazopoulou, Evdoxia
title: Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis*
date: 2021-07-13
journal: Crit Care Med
DOI: 10.1097/ccm.0000000000005195
sha: 402569efacfbaf33d970d2808aa1e84e4775d33b
doc_id: 902164
cord_uid: 8vvhen5w

OBJECTIVE: Coronavirus disease 2019 is a heterogeneous disease most frequently causing respiratory tract infection, which can induce respiratory failure and multiple organ dysfunction syndrome in its severe forms. The prevalence of coronavirus disease 2019–related sepsis is still unclear; we aimed to describe this in a systematic review. DATA SOURCES: MEDLINE (PubMed), Cochrane, and Google Scholar databases were searched based on a prespecified protocol (International Prospective Register for Systematic Reviews: CRD42020202018). STUDY SELECTION: Studies reporting on patients with confirmed coronavirus disease 2019 diagnosed with sepsis according to sepsis-3 or according to the presence of infection-related organ dysfunctions necessitating organ support/replacement were included in the analysis. The primary end point was prevalence of coronavirus disease 2019–related sepsis among adults hospitalized in the ICU and the general ward. Among secondary end points were the need for ICU admission among patients initially hospitalized in the general ward and the prevalence of new onset of organ dysfunction in the ICU. Outcomes were expressed as proportions with respective 95% CI. DATA EXTRACTION: Two reviewers independently screened and reviewed existing literature and assessed study quality with the Newcastle-Ottawa Scale and the Methodological index for nonrandomized studies. DATA SYNTHESIS: Of 3,825 articles, 151 were analyzed, only five of which directly reported sepsis prevalence. Noting the high heterogeneity observed, coronavirus disease 2019–related sepsis prevalence was 77.9% (95% CI, 75.9–79.8; I(2) = 91%; 57 studies) in the ICU, and 33.3% (95% CI, 30.3–36.4; I(2) = 99%; 86 studies) in the general ward. ICU admission was required for 17.7% (95% CI, 12.9–23.6; I(2) = 100%) of ward patients. Acute respiratory distress syndrome was the most common organ dysfunction in the ICU (87.5%; 95% CI, 83.3–90.7; I(2) = 98%). CONCLUSIONS: The majority of coronavirus disease 2019 patients hospitalized in the ICU meet Sepsis-3 criteria and present infection-associated organ dysfunction. The medical and scientific community should be aware and systematically report viral sepsis for prognostic and treatment implications.

C oronavirus disease 2019 (COVID-19) is a recognized pandemic that spread rapidly around the globe and led to millions of confirmed cases and deaths worldwide (1) . Severe forms are complicated by respiratory insufficiency and need for invasive mechanical ventilation (IMV) (2) . Reported cases often present with other organ failures; such involvement resembles the systemic counterparts of bacterial and viral sepsis (3) (4) (5) . The current Sepsis-3 definitions define sepsis as a life-threatening organ dysfunction due to the dysregulated host response to an infection. The same definitions introduce the Sequential Organ Failure Assessment (SOFA) score as measure of organ dysfunction (6) . According to World Health Organization, manifestations of sepsis and septic shock can be the final pathway of infections by highly transmissible pathogens of public health concern, like avian and swine influenza viruses, or corona viruses (7) . Respiratory failure of COVID-19 is accompanied by complex host immune dysregulation (8) . As a consequence, all elements of the Sepsis-3 definition may apply for COVID-19 (9) .

With this in mind, we systematically investigated peer-reviewed published literature to describe the prevalence of COVID-19-related sepsis. In parallel, the prevalence of new-onset organ dysfunctions, organ replacements, and need for ICU admission were assessed as surrogates for viral sepsis.

This review was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement (10) , based on a prespecified protocol (International Prospective Register for Systematic Reviews: CRD42020202018).

Eligibility criteria were defined using the Population, Intervention, Comparison, Outcome (PICO) statement; P: hospitalized patients with confirmed COVID-19. Duration of follow-up was defined by the length of hospital stay. I: diagnosis of sepsis and any infection-related organ dysfunction or need for organ replacement (dialysis, mechanical ventilation [MV] , extracorporeal membrane oxygenation [ECMO] , and liver replacement). Sepsis was primarily defined according to Sepsis-3, as any SOFA score greater than or equal to 2 at admission; quick SOFA (qSOFA) score greater than or equal to 2, severe sepsis according to Sepsis 1/2 criteria, or relevant International Classification of Diseases (ICD) codes were acceptable alternative definitions (6, 7, 11) . Organ dysfunction was also reported based on admission values, whereas organ replacement was assessed throughout the follow-up period. C: no control group was included, whereas O was the prevalence of sepsis, infection-related organ dysfunction, need for organ support/ replacement, and sepsis-related mortality. All randomized and nonrandomized trials and observational studies, published as full text in English, were included, whereas editorials, conference abstracts, animal studies, case reports, articles not in English or not providing full text, and studies with fewer than 30 participants were excluded. Systematic reviews were consulted for additional information but were excluded to avoid duplication.

Search was conducted on August 27, 2020, and repeated on October 3, 2020, and on March 29, 2021, by two independent authors (E.Ka., E.Ky.) across MEDLINE (PubMed), Cochrane, and Google Scholar databases using the following terms: "COVID-19" or "SARS-CoV-2" and "sepsis, " "organ failure, " "organ dysfunction. " Detailed strategy is provided in Supplement (http://links.lww.com/CCM/G588).

Both reviewers assessed all articles by title and, then, by abstract and full text to find those eligible. The following data were extracted: first author name, country of origin, publication time, study design, total number of patients, criteria for enrollment, number of patients presenting sepsis, criteria used to assess sepsis, new onset organ dysfunction, organ support/replacement therapy, number of patients requiring ICU, ICU/hospital discharge, and mortality. Any controversies were resolved by a third reviewer (E.J.G.B). The corresponding authors were contacted to provide relevant data.

For studies allowing extraction of SOFA score greater than or equal to 2 for different organ dysfunctions, a conservative approach was followed, and only the organ with the maximum number of affected patients within the cohort was considered, for example, in a cohort with x patients presenting respiratory SOFA greater than or equal to 2, y patients presenting cardiovascular SOFA greater than or equal to 2, and x > y, the number of patients considered to have sepsis would be defined as x. Among studies reporting medians (interquartile range [IQR]), outcomes were calculated as the minimum n observed, for example, if SOFA score at baseline was reported as 4 (2) (3) (4) (5) (6) , then at least 75% of the study population was expected to have a SOFA score greater than or equal to 2. For studies reporting on both ICU and general ward patients, these were included in the analysis with the total number of ICU or general ward patients as denominator.

Each study was evaluated by both reviewers with the Newcastle-Ottawa scale for observational studies (12) .

Since not all parameters of this scale were applicable in case of single cohorts, their quality was also evaluated with the methodological index for nonrandomized studies (MINORS) (13) . Furthermore, the level of certainty in extraction of the primary endpoint was assessed using a three-star scale, from zero (one star) to intermediate/high uncertainty (three stars). Studies providing the exact number of patients fulfilling Sepsis-3 criteria (in the original publication or after contacting corresponding authors) were qualified as zero uncertainty; studies reporting baseline median SOFA score (IQR) were qualified as low; studies allowing extraction of SOFA score greater than or equal to 2, based at least on one reported specific organ dysfunction at baseline, were characterized as intermediate/high. The highest level of certainty achievable within the study was used to assess sepsis prevalence, for example, if x patients were considered to have sepsis according to our criteria for low certainty and y according to criteria for intermediate, we would report sepsis prevalence as x, even when x < y.

The primary end point was the prevalence of COVID-19-related sepsis among adults hospitalized in the ICU and general ward, expressed as proportion (95% CIs). Secondary endpoints were: 1) the prevalence of new onset infection-related organ dysfunction in the ICU, 2) the prevalence of organ support and/or replacement (IMV and noninvasive MV, vasopressors, ECMO, liver, and renal replacement therapy) in the ICU, 3) the prevalence of ICU admission, 4) mortality of COVID-19 patients with sepsis, and 5) the prevalence of pediatric COVID-19-related sepsis. The outcome measure for each secondary outcome was the proportion (95% CI) of patients presenting the respective outcome.

The meta-analyses were performed using the R software Version 4.0.2 (R Core Team, The University of Auckland, Auckland, New Zealand) after installing the packages "meta, " "metaphor, " and "dmetar" (14, 15) . In all cases, the random effects (DerSimonian and Laird) model was employed (16) . For each analysis, the corresponding forest plot was produced, whereas publication bias was assessed with the Egger test via funnel plot asymmetry (17) . Subgroup differences were reported by the Q-statistic (18) .

The following analyses were planned regarding the primary endpoint: 1) per level of uncertainty regarding the extraction of the primary end point, as previously described, 2) per geographical location of studies, 3) per period of study enrollment, and 4) per nonpulmonary versus pulmonary acute organ dysfunction assessment, since COVID-19 is often associated with hypoxemic respiratory failure.

The literature search yielded 3,825 records; after removal of duplicates and records with irrelevant title, 834 were screened full text by the reviewers. After applying exclusion criteria, 151 studies including a total of 218,184 patients were finally analyzed ( Fig. 1) .

Of the 151 included studies, mainly observational retrospective, 104 were published in 2020 and 47 in 2021 121, 122, 129, 133, 144, 149, 152) , in eight of which describing bacterial complications during hospitalization for COVID-19; only one described sepsis as a presenting feature of COVID-19 (133) .

Data regarding the prevalence of COVID-19-related sepsis were available from 56 studies in the ICU (38,058 adult patients).

The pooled estimate was 77.9% (95% CI, 75.9-79.8; I 2 = 91%), as shown in Figure 2 , with evidence of publication bias (p = 0.012; Supplementary Fig. 1 , http:// links.lww.com/CCM/G588). The lowest level of heterogeneity was achieved among studies with zero (I 2 = 67%) and low (I 2 = 60%) uncertainty. Conversely, heterogeneity remained substantial (I 2 = 97%) among studies with intermediate/high uncertainty (Fig. 2 ). Subgroup analysis per geographical location reduced without eliminating heterogeneity (I 2 ≥ 76%), and the meta-analytical outcome remained constant among subgroups (test for subgroup differences: p = 0.543; Supplementary Fig. 2 , http://links.lww. com/CCM/G588). Analysis per chronological period also failed to eliminate heterogeneity (I 2 ≥ 76%). A slight increase in sepsis prevalence of 79.5% (95% CI, 76.8-82.0; I 2 = 94%) was observed during the second period of the pandemic (test for subgroup differences: p = 0.047; Supplementary Fig. 3 , http://links.lww.com/ CCM/G588). None of the included studies reported data as of 2021. Subgroup analysis of pulmonary versus nonpulmonary acute organ dysfunction could not be performed in the ICU; due to IMV, the presence of a pulmonary component for SOFA could not be excluded. Fig. 4 , http://links.lww.com/CCM/G588). Studies with zero and low uncertainty had increased viral sepsis prevalence (test for subgroup differences: p = 0.0009; Supplementary Fig. 4 , http://links.lww.com/CCM/ G588).

Subgroup analysis according to nonpulmonary (n = 22) versus pulmonary (n = 64) acute organ dysfunction provided a pooled estimate of sepsis of 21.7% (95% CI, 18.7-25.1; I 2 = 95%) and 37.8% (95% CI, 34.1-41.7; I 2 = 99%), respectively (test of subgroup differences: p < 0.001, Supplementary Fig. 5 , http://links. lww.com/CCM/G588).

Based on the above, the overall pooled sepsis prevalence estimate among 218,184 COVID-19 patients, irrespectively of ICU or non-ICU admission, was 51.6 (95% CI, 47.6-55.5; I 2 = 100%), as shown in Supplementary Figure 6 (http://links.lww.com/CCM/G588).

Organ Dysfunctions in the ICU. Organ dysfunctions were assessed as defined in the original publications. Septic shock was defined by Sepsis-3 criteria (6) and acute respiratory distress syndrome (ARDS) by the Berlin definition (170) in all studies but one (129) , which used the Kigali modification (171) . A synthesis of prevalence estimates of organ dysfunctions in adults in the ICU is presented in Table 1 and Supplementary Fig. 8 , http://links.lww.com/CCM/G588).

Need for ICU Admission. ICU admission was evaluated, among 57 studies (165,008 patients initially hospitalized in the general ward), as surrogate for the presence of COVID-19-related organ dysfunction or support. A pooled estimate of 17.7% (95% CI, 12.9-23.6; I 2 = 100%) of those patients required ICU admission (Supplementary Fig. 9 , http://links.lww.com/ CCM/G588).

Mortality. Mortality could not be assessed separately for patients with and without sepsis, since none of the studies reported such outcomes. To overcome this, ICU mortality and mortality among patients under IMV were investigated as surrogates of sepsisrelated mortality. ICU mortality was 33.0% (95% CI, 29.1-37.2; I 2 = 97%) (Fig. 3A) , whereas IMV-related mortality was 42.0% (95% CI, 36.8-47.4; I 2 = 94%) Fig. 12 , http:// links.lww.com/CCM/G588).

In this systematic review and meta-analysis, we showed that COVID-19-related sepsis, based on Sepsis-3, is present in a considerable proportion of hospitalized patients; 77.9% of adult patients in the ICU have viral sepsis. This is also the case for 33.3% Prevalence (%) is considered the pooled estimate of each organ dysfunction as calculated in the respective meta-analysis of the respective studies providing such data, taking into consideration different weights of each study in the meta-analysis (resulting from number of patients in each meta-analyzed trial). Prevalence (%) is considered the pooled estimate of each organ replacement as calculated in the respective meta-analysis of the respective studies providing such data, taking into consideration different weights of each study in the meta-analysis (resulting from number of patients in each meta-analyzed trial).

of patients originally admitted in the general ward, 17.7% of which are transferred to the ICU. ARDS is the most common organ dysfunction, followed by septic shock. Despite separate analysis for ICU and general ward populations, adult and pediatric, and conservative reporting with the highest level of certainty, heterogeneity remained high. The most probable explanation was the absence of reporting of specific numbers of patients with greater than or equal to 2 SOFA values in most studies. This was limited when raw data were used after contacting the authors.

Interestingly, COVID-19-related sepsis was rarely reported as "sepsis" syndrome within the studies searched. On the contrary, of the nine articles where the term was used, (70, 103, 121, 122, 129, 133, 144, 149, 152) , eight reported it as complication of secondary bacterial infections. This raises a question of awareness regarding viral sepsis in the medical and scientific community. Sepsis is traditionally seen as a consequence of bacterial infection but may occur regardless of the type of pathogen (172) . Although viral sepsis, in the form of ARDS, shock, and other organ-failures, has also been associated with influenza A, authors still focus on secondary bacterial infections (173, 174) . In COVID-19, low proportion (7%) of hospitalized patients suffer bacterial coinfection or secondary infection; this is slightly higher for ICU patients (175, 176) , whereas the frequency of opportunistic infections is likely to rise after the widespread introduction of dexamethasone (177) . Thus, reporting of septic episodes should be separate for viral and bacterial pathogens throughout hospitalization, but it is unlikely that sepsis estimates within the current study reflect bacterial coinfection. Given that most of the evidence comes from retrospective, observational studies, where a standardized assessment of SOFA components may be complex, the Centers for Disease Control and Prevention Adult Sepsis Event organ dysfunction criteria optimized for electronic health record systems criteria for Adult Sepsis Events (178) may be an interesting, simpler, nonscalar and based on fewer parameters alternative to facilitate sepsis reporting. More interestingly, by highlighting the importance of microbiological documentation, it may help distinguishing inhospital viral from secondary bacterial infection-related sepsis.

The above analysis highlights that COVID- 19 is not yet perceived as viral sepsis, which is probably underreported. The trials included were not designed to answer this clinical question. This is considered as a major source of heterogeneity in our results; increased awareness might prompt future publications to report more precisely and systematically SOFA components. Nevertheless, this would not eliminate clinical heterogeneity due to differences in cohorts, time periods, hospital or geographical settings, different levels of care, different timing of assessment, and variable immune response of the host; heterogeneity remained substantial even after subgroup analysis by geographical settings and time periods and all of the above are acknowledged as limitations within this study and known features of sepsis studies in general. A recent meta-analysis focusing on a harder end point than ours, that is, IMV-associated mortality, reported as high as 45%, could not eliminate heterogeneity, attributed to different locations and practices concerning intensive care allocation (179) .

Children are less affected by the virus, but, if hospitalized, still at risk of organ failure. The use of organ dysfunctions as pediatric sepsis indicator might have been conservative and did not fully capture patients with multiinflammatory syndrome associated to COVID-19, a novel entity described in children with high inflammatory features and multiple organ involvement (180) , as potential equivalent of adult sepsis.

Underlying pathophysiological mechanisms of multiorgan injury in COVID-19 may be partly unique to severe acute respiratory syndrome coronavirus 2 (direct viral toxicity) and partly common with bacterial sepsis, such as endothelial cell damage, thromboinflammation, dysregulated immune system activation coupled with tissue damage by neutrophils, monocytes, and lymphocytes, and dysregulation of the rennin-angiotensin-aldosterone system (181) (182) (183) (184) (185) (186) (187) . Overlap between severe COVID-19 and sepsis, as shown in the current analysis, may be neither surprising nor unexpected, but quantifying the link has important treatment and policy-making implications. Following the paradigm of bacterial sepsis, guidelines for COVID-19 management have been issued highlighting the importance of supportive care in critically ill patients (188) . Pathogenspecific treatments, such as remdesivir, may accelerate clinical recovery (189) , whereas immune-targeting therapies have been tested through clinical trials, with conflicting results (93, (190) (191) (192) (193) (194) . Further research is needed to identify which patients would benefit from such interventions. On a public health level, this awareness might lead to prioritizing national sepsis-infection action plans, to deal with current and future pandemics.

To the best of our knowledge, this is the first study to address in a systematic way the presence of COVID-19related sepsis, according to Sepsis-3 criteria, and the first to provide pooled estimates of specific organ dysfunctions. Results are highly heterogeneous and should be interpreted with caution, given the paucity of data on SOFA components and the conservative approach used for SOFA score extraction. Higher precision resulted in increased detection of sepsis, and every effort should be made to identify patients at high risk for those complications.

A considerable proportion of patients with COVID-19 meet Sepsis-3. True prevalence is probably underestimated, and estimates increase with improved data reporting quality and limiting uncertainty. Lessons learned from bacterial sepsis may apply, in terms of early recognition by means of SOFA score, importance of supportive care, as well as potential benefit from immune regulating strategies. Serum hs-cTnI level in risk stratification and the prediction of

2019?gclid=Cj0KCQiAhs79BRD0ARIs AC6XpaXhxHeN64r7-j5rvv0ZDtNGxNkA0e2EWCAUr8QWWj-qi_ PPrXOljroaAjXBEALw_wcB

COVID-19 Lombardy ICU Network: Risk factors associated with mortality among patients with COVID-19 in intensive care units in

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in

The third international consensus definitions for sepsis and septic shock (Sepsis-3)

World Health Organization: Improving the Prevention, Diagnosis and Clinical Management of Sepsis

Complex immune dysregulation in COVID-19 patients with severe respiratory failure

SARS-CoV-2 and viral sepsis: Observations and hypotheses

Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) 2015 statement

SCCM/ESICM/ACCP/ATS/ SIS international sepsis definitions conference

Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses

Methodological index for nonrandomized studies (minors): Development and validation of a new instrument

How to perform a metaanalysis with R: A practical tutorial

Conducting meta-analyses in R with the metafor package

Meta-analysis in clinical trials

Bias in metaanalysis detected by a simple, graphical test

How to use a subgroup analysis: Users' guide to the medical literature

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series

Clinical characteristics and outcomes of patients with severe covid-19 with diabetes

15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: An ambispective observational cohort study

Critical Care Medicine www.ccmjournal.org 30-day fatality in COVID-19 patients with no prior cardiovascular disease

Clinical characteristics of elderly patients with COVID-19 in Hunan Province, China: A multicenter, retrospective study

Critical Covid-19 France Investigators: Pulmonary embolism in COVID-19 patients: A French multicentre cohort study

Henry Ford COVID-19 Task Force: Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status

Characteristics and outcomes of coronavirus disease patients under nonsurge conditions

Clinical characteristics and predictors of disease progression in severe patients with COVID-19 infection in Jiangsu Province, China: A descriptive study

Acute physiology and chronic health evaluation II score as a predictor of hospital mortality in patients of coronavirus disease 2019

Incidence of venous thromboembolism in hospitalized patients with COVID

Clinical characteristics, management and in-hospital mortality of patients with COVID-19 in

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia

Prognostic factors in Spanish COVID-19 patients: A case series from Barcelona

Pulmonary embolism or thrombosis in ARDS COVID-19 patients: A French monocenter retrospective study

Longitudinal association between markers of liver injury and mortality in COVID-19 in China

A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19

ICU outcomes of COVID-19 critically ill patients: An international comparative study

Spanish Society of Nephrology COVID-19 Group: Use of tocilizumab in kidney transplant recipients with COVID-19

Association of troponin levels with mortality in Italian patients hospitalized with coronavirus disease 2019: Results of a multicenter study

Cytokine levels in critically Ill patients with COVID-19 and other conditions

Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19

Increased mortality in patients with severe SARS-CoV-2 infection admitted within seven days of disease onset

Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients

Association between procalcitonin levels and duration of mechanical ventilation in COVID-19 patients

Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: A multicentre observational study

Extracorporeal membrane oxygenation for coronavirus disease 2019-induced acute respiratory distress syndrome: A multicenter descriptive study

et al; and the Emory COVID-19 Quality and Clinical Research Collaborative: ICU and ventilator mortality among critically ill adults with coronavirus disease 2019

Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: A comparative cohort study from a US 'hot spot

Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2 infection (MIS-C): A multi-institutional study from New York City

Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19

AKI in hospitalized patients with and without COVID-19: A comparison study

Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: A multicentre observational study

Belgian Collaborative Group on COVID-19 Hospital Surveillance: Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: A nationwide observational study of 8075 participants

Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients

Group members: Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study

CAPE COVID Trial Group and the CRICS-TriGGERSep Network: Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: A randomized clinical trial

Awake prone positioning does not reduce the risk of intubation in COVID-19 treated with high-flow nasal oxygen therapy: A multicenter, adjusted cohort study

Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia

Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study

Severity of respiratory failure at admission and in-hospital mortality in patients with COVID-19: A prospective observational multicentre study

Risk factors for the critical illness in SARS-CoV-2 infection: A multicenter retrospective cohort study

Collaborative Group: Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study

Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: An observational retrospective study

Outcomes and clinical practice in patients with COVID-19 admitted to the intensive care unit in Montréal, Canada: A descriptive analysis

Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study

Machine learning in predicting respiratory failure in patients with COVID-19 pneumonia-challenges, strengths, and opportunities in a global health emergency

Spanish Pediatric Intensive Care Society working group on SARS-CoV-2 infection: Severe manifestations of SARS-CoV-2 in children and adolescents: From COVID-19 pneumonia to multisystem inflammatory syndrome: A multicentre study in pediatric intensive care units in Spain

High rates of 30-day mortality in patients with cirrhosis and COVID-19

Brescia Renal COVID task force: Kidney transplant patients with SARS-CoV-2 infection: The Brescia renal COVID task force experience

Serum hydrogen sulfide and outcome association in pneumonia by the SARS-CoV-2 coronavirus

Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study

Neutrophil-tolymphocyte ratio and outcomes in Louisiana COVID-19 patients

Clinical course of 195 critically ill COVID-19 patients: A retrospective multicenter study

Characteristics and outcomes of hospitalised patients with acute kidney injury and COVID-19

Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study

Risk factors associated with 28-day all-cause mortality in older severe COVID-19 patients in Wuhan, China: A retrospective observational study

Novel risk scoring system for predicting acute respiratory distress syndrome among hospitalized patients with coronavirus disease

Effect of early vs. delayed or no intubation on clinical outcomes of patients with COVID-19: An observational study

COVID-19 in critically ill patients in North Brabant, the Netherlands: Patient characteristics and outcomes

Outcomes for patients with COVID-19 admitted to Australian intensive care units during the first four months of the pandemic

COVOCA Study Group: Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study

Clinical features and outcome of maintenance hemodialysis patients with COVID-19 from a tertiary nephrology care center in Romania

COLD Consortium: Liver injury in liver transplant recipients with coronavirus disease 2019 (COVID-19): U.S. multicenter experience

Low 25-hydroxyvitamin D levels on admission to the intensive care unit may predispose COVID-19 pneumonia patients to a higher 28-day mortality risk: A pilot study on a Greek ICU cohort

Acute kidney injury in pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus-2 pandemic: Experience from PICUs across United Kingdom

Outcomes in mechanically ventilated patients with hypoxaemic respiratory failure caused by COVID-19

National Heart, Lung, and Blood Institute PETAL Clinical Trials Network: Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: A randomized clinical trial

NW Collaborative Organisation for Respiratory Research: Utility of established prognostic scores in COVID-19 hospital admissions: Multicentre prospective evaluation of CURB-65, NEWS2 and qSOFA

Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19

Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the cardio-COVID-Italy multicentre study

Risk factors for severe COVID-19 in middle-aged patients without comorbidities: A multicentre retrospective study

Mexico COVID-19 Critical Care Collaborative Group: Outcomes of patients with COVID-19 in the intensive care unit in Mexico: A multicenter observational study

Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: A multicenter, single-blind, randomized control trial

Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: An observational cohort study

ICNARC COVID-19 Team: Prognostic factors for 30-day mortality in critically ill patients with coronavirus disease 2019: An observational cohort study

COVID19-Researchers: The value of C-reactive protein-to-lymphocyte ratio in predicting the severity of SARS-CoV-2 pneumonia

RCI-COVID-19 study group: A higher BMI is not associated with a different immune response and disease course in critically ill COVID-19 patients

Clinical characteristics and outcomes of critically ill patients with COVID-19 in Kobe, Japan: A single-center, retrospective, observational study

Characteristics and outcomes in hospitalized COVID-19 patients during the first 28 days of the spring and autumn pandemic waves in Milan: An observational prospective study

DMC-19 Study Group and the North American Alliance for the Study of Digestive Manifestations of COVID-19: Outcomes of COVID-19 among hospitalized health care workers in North America

Unexpectedly high frequency of enterococcal bloodstream infections in coronavirus disease 2019 patients admitted to an Italian ICU: An observational study

Risk factors for mortality of critically ill patients with COVID-19 receiving invasive ventilation

Group on behalf of the REVA Network and the COVID-ICU Investigators: Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: A prospective cohort study

STOP-COVID Investigators: AKI treated with renal replacement therapy in critically ill patients with COVID-19

AEPC COVID-19 Rapid Response Team*: Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe

PREDICO Study Group: Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: A multicentre study

Oral anticoagulation and clinical outcomes in COVID-19: An Italian multicenter experience

French Group of Lung Transplantation: COVID-19 in lung transplant recipients

COVID-19 Intensive Care International Study Group: Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): A multicentre cohort study

coVAPid study Group: Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: A European multicenter cohort study

COVID-19 and multisystem inflammatory syndrome in Latin www.ccmjournal.org

American children: A multinational study

The modified NUTRIC score can be used for nutritional risk assessment as well as prognosis prediction in critically ill COVID-19 patients

SEMI-COVID-19 Network: Clinical characteristics and risk factors for mortality in very old patients hospitalized with COVID-19 in Spain

COVID-19 and myocardial injury in a Brazilian ICU: High incidence and higher risk of in-hospital mortality

French Covid-19 Paediatric Inflammation Consortium: Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children

Association of D-dimer elevation with inflammation and organ dysfunction in ICU patients with COVID-19 in Wuhan, China: A retrospective observational study

Risk factors and outcomes for acute respiratory failure in coronavirus disease 2019: An observational cohort study

Acute kidney injury is associated with in-hospital mortality in older patients with COVID-19

Clinical progression and outcomes of 260 patients with severe COVID-19: An observational study

T-helper cell subset response is a determining factor in COVID-19 progression

SEMI-COVID-19 Network: Healthcare workers hospitalized due to COVID-19 have no higher risk of death than general population. Data from the Spanish SEMI-COVID-19 registry

Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study

Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial

Mechanical ventilation and mortality among 223 critically ill patients with coronavirus disease 2019: A multicentric study in Germany

Clinical characteristics and outcomes of patients with severe COVID-19 induced acute kidney injury

A single-centre, prospective cohort study of COVID-19 patients admitted to ICU for mechanical ventilatory support

Myocardial injury on admission as a risk in critically ill COVID-19 patients: A retrospective in-ICU study

Prevalence and outcome of dysnatremia in patients with COVID-19 compared to controls

Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial

Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza

Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group: Outcomes of patients with coronavirus disease 2019 receiving organ support therapies: The international viral infection and respiratory illness universal study registry

HPG23 Covid-19 Study Group: Covid-19 and gender: Lower rate but same mortality of severe disease in women-an observational study

Extra-pulmonary complications of 45 critically ill patients with COVID-19 in Yichang, Hubei province, China: A single-centered, retrospective, observation study

HLA genetic polymorphisms and prognosis of patients with COVID-19

Tri-State Pediatric COVID-19 Research Consortium: Severe acute respiratory syndrome coronavirus 2 clinical syndromes and predictors of disease severity in hospitalized children and youth

Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission

Trends in intensive care for patients with COVID-19 in England, Wales, and Northern Ireland

Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019

Acute respiratory distress syndrome: The Berlin definition

Hospital incidence and outcomes of the acute respiratory distress Critical Care Medicine www.ccmjournal.org syndrome using the Kigali modification of the Berlin definition

Does severe acute respiratory syndrome coronavirus 2 cause sepsis?

Canadian Critical Care Trials Group H1N1 Collaborative: Critically ill patients with 2009 influenza A(H1N1) infection in Canada

ANZICS: ICU admissions for sepsis or pneumonia in Australia and New Zealand in 2017

Co-infections in people with COVID-19: A systematic review and meta-analysis

Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis

Bacterial and fungal superinfections in critically ill patients with COVID-19

Centers for Disease Control and Prevention: Hospital Toolkit for Adult Sepsis Surveillance. 2021. Available at

Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. A meta-analysis

Centers for Disease Control and Prevention: Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease 2019 (COVID-19). 2021. Available at

Extrapulmonary manifestations of COVID-19

China Medical Treatment Expert Group for Covid-19: Clinical characteristics of coronavirus disease 2019 in China

Multiorgan and renal tropism of SARS-CoV-2

Explore COVID-19 IPH group; Explore COVID-19 Marseille Immunopole group: Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis

Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression

Anticoagulation in COVID-19: A systematic review, metaanalysis, and rapid guidance from Mayo Clinic

Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)

ACTT-1 Study Group Members: Remdesivir for the treatment of Covid-19-final report

Dexamethasone in hospitalized patients with Covid-19-preliminary report

A Propensity-matched cohort study of tocilizumab in patients with coronavirus disease 2019

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study

Favorable anakinra responses in severe covid-19 patients with secondary hemophagocytic lymphohistiocytosis

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): An exploratory, open-label, phase 2 randomised controlled trial